TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07794670: Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease

Sponsor: NewAmsterdam Pharma · Phase: PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 400 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$12,416,000

Rescue Site Savings

+$8,186,800

Unlock Full NCT07794670 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07794670 Rescue Dossier →